Roche Holding AG (XSWX:RO) Stock Based Compensation: CHF857 Mil (TTM As of Dec. 2025)


XSWX:RO Roche Holding AG XSWX:RO
77 GF Score
Price CHF342.00
GF Value CHF269.42
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Stock Based Compensation?

Roche Holding AG XSWX:RO -0.47% 77 Stock Based Compensation is CHF857 Mil as of Dec. 2025. GuruFocus rates XSWX:RO with a GF Score™ of 77/100 and a GF Value™ of CHF269.42 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Roche Holding AG's Stock Based Compensation for the six months ended in Dec. 2025 was CHF465 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was CHF857 Mil.

Roche Holding AG Stock Based Compensation Related Terms

Roche Holding AG Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Stock Based Compensation Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 663.00 738.00 830.00 855.00 857.00

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 447.00 407.00 448.00 392.00 465.00
XSWX:RO
77GF Score
Roche Holding AG XSWX:RO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF857 Mil.

What does a Stock Based Compensation of CHF857 Mil mean?
Roche Holding AG (XSWX:RO) has a Stock Based Compensation of CHF857 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Roche Holding AG and its competitors.
Is Roche Holding AG's Stock Based Compensation too high?
Roche Holding AG's current Stock Based Compensation is CHF857 Mil. Overall, Roche Holding AG has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Stock Based Compensation compare to LLY and JNJ?
Roche Holding AG's Stock Based Compensation of CHF857 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Roche Holding AG and its competitors. Roche Holding AG's current Stock Based Compensation is CHF857 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF269.42, compared to a current price of CHF342.00 — trading 26.9% above its estimated fair value. The current Stock Based Compensation is CHF857 Mil. Roche Holding AG's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Stock Based Compensation is CHF857 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF342.00 is trading 26.9% above its estimated GF Value™ of CHF269.42. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:RO:

  • Stock Based Compensation: CHF857 Mil
  • GF Value™: CHF269.42 vs. price of CHF342.00 (26.9% above fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
77GF Score

Get the complete analysis for XSWX:RO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF342.00
Price
CHF269.42
GF Value